Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Nov;8(6):591-605.
doi: 10.1016/j.jare.2017.06.006. Epub 2017 Jun 27.

Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review

Ahmed M Al-Abd  1   2   3 , Abdulmohsin J Alamoudi  2 , Ashraf B Abdel-Naim  2   4 , Thikryat A Neamatallah  2 , Osama M Ashour  2   5
Affiliations
Review

Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review

Ahmed M Al-Abd et al. J Adv Res. 2017 Nov.

Abstract

Recent strategies for the treatment of cancer, other than just tumor cell killing have been under intensive development, such as anti-angiogenic therapeutic approach. Angiogenesis inhibition is an important strategy for the treatment of solid tumors, which basically depends on cutting off the blood supply to tumor micro-regions, resulting in pan-hypoxia and pan-necrosis within solid tumor tissues. The differential activation of angiogenesis between normal and tumor tissues makes this process an attractive strategic target for anti-tumor drug discovery. The principles of anti-angiogenic treatment for solid tumors were originally proposed in 1972, and ever since, it has become a putative target for therapies directed against solid tumors. In the early twenty first century, the FDA approved anti-angiogenic drugs, such as bevacizumab and sorafenib for the treatment of several solid tumors. Over the past two decades, researches have continued to improve the performance of anti-angiogenic drugs, describe their drug interaction potential, and uncover possible reasons for potential treatment resistance. Herein, we present an update to the pre-clinical and clinical situations of anti-angiogenic agents and discuss the most recent trends in this field.

Keywords: Angiogenesis inhibitors; Natural products; Receptor protein-tyrosine kinase; Tumor microenvironment.

PubMed Disclaimer

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Molecular aspects of different angiogenic pathways; brief diagrammatic summary for different molecular pathways involved in angiogenesis. Designed using Mind The Graph™, Zendesk Inc., San Francisco, CA, USA.
Fig. 2
Fig. 2
Diagrammatic illustration for the interaction between monoclonal antibodies with pro-angiogenic ligand or receptor (A) and the interaction between decoy receptor and soluble pro-angiogenic ligand (B). Designed using Mind The Graph™, Zendesk Inc., San Francisco, CA, USA.
Fig. 3
Fig. 3
Diagrammatic sketch for the molecular bases of RTKI’s action (A) and example of the versatile interaction between different investigational new RTKIs and pro-angiogenic receptors (B). Designed using Mind The Graph™, Zendesk Inc., San Francisco, CA, USA.
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. - PubMed
    1. 1950 mortality data – CDC/NCHS, NVSS, mortality Revised. 2002 mortality Data-NVSR-Death final Data 2002-Volume 53, No. 5. Cost data from American Cancer Society Cancer & Figures 2005; 2002.
    1. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. - PubMed
    1. Al-Abd A.M., Aljehani Z.K., Gazzaz R.W., Fakhri S.H., Jabbad A.H., Alahdal A.M. Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors. J Control Release. 2015;219:269–277. - PubMed
    1. Albini A., Tosetti F., Li V.W., Noonan D.M., Li W.W. Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol. 2012;9(9):498–509. - PubMed